New published article: Guibert et al., 2024

Congratulations to Pr. Kessler and colleagues on the publication of their article on the impact of treatment with the MiniMedᵀᴹ 780 insulin pump on blood glucose levels in pregnant women with type 1 diabetes (T1D) in the journal Diabetes Technology & Therapeutics. We are delighted to have contributed to the success of this article!

T1D is a risk factor for 𝐜𝐨𝐦𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐝𝐮𝐫𝐢𝐧𝐠 𝐩𝐫𝐞𝐠𝐧𝐚𝐧𝐜𝐲, such as 𝐩𝐫𝐞𝐦𝐚𝐭𝐮𝐫𝐞 𝐛𝐢𝐫𝐭𝐡, 𝐩𝐫𝐞-𝐞𝐜𝐥𝐚𝐦𝐩𝐬𝐢𝐚, 𝐚𝐧𝐝 𝐢𝐧𝐭𝐫𝐚𝐮𝐭𝐞𝐫𝐢𝐧𝐞 𝐝𝐞𝐚𝐭𝐡. Careful monitoring of blood glucose levels can 𝐫𝐞𝐝𝐮𝐜𝐞 𝐭𝐡𝐞 𝐫𝐢𝐬𝐤 of fetal death and malformations during pregnancy in T1D women. The authors evaluated the impact of blood glucose monitoring with the 𝐌𝐢𝐧𝐢𝐌𝐞𝐝ᵀᴹ 𝐢𝐧𝐬𝐮𝐥𝐢𝐧 𝐩𝐮𝐦𝐩 in T1D patients on the evolution of blood glucose levels and neonatal and maternal complications.

A total of 13 pregnant women were included in the study. Mean gestational age at birth was 31 weeks. The time spent in the target blood glucose range varied between 46% and 66% during pregnancy. Overnight, this time was over 𝟕𝟎% 𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐨𝐮𝐭 𝐩𝐫𝐞𝐠𝐧𝐚𝐧𝐜𝐲. The mean glycated hemoglobin was 6.4% at the birth of the children, who weighed an average of 3.134 kg. 𝐂𝐨𝐦𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐰𝐞𝐫𝐞 𝐫𝐞𝐩𝐨𝐫𝐭𝐞𝐝 in the newborns, including macrosomia (5/14) and neonatal hypoglycemia (2/14), and in the mothers: preeclampsia (5/13) and cesarean section (9/13).

Although glycemic control with the MiniMedᵀᴹ insulin pump was 𝐨𝐯𝐞𝐫𝐚𝐥𝐥 𝐬𝐚𝐭𝐢𝐬𝐟𝐚𝐜𝐭𝐨𝐫𝐲, the recommended results were only achieved during the night-time periods. Complications 𝐫𝐞𝐦𝐚𝐢𝐧𝐞𝐝 𝐧𝐨𝐧-𝐧𝐞𝐠𝐥𝐢𝐠𝐢𝐛𝐥𝐞, both for newborns and patients The article is already available on the journal's website! 𝐃𝐎𝐈: 𝟏𝟎.𝟏𝟎𝟖𝟗/𝐝𝐢𝐚.𝟐𝟎𝟐𝟑.𝟎𝟐𝟔𝟕